These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 9563885

  • 41. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW.
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [Abstract] [Full Text] [Related]

  • 42. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.
    Hainsworth PJ, Henderson MA, Stillwell RG, Bennett RC.
    Eur J Surg Oncol; 1991 Feb; 17(1):9-15. PubMed ID: 1671658
    [Abstract] [Full Text] [Related]

  • 43. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
    Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R.
    Cancer Res; 1993 Nov 01; 53(21):5251-61. PubMed ID: 8106145
    [Abstract] [Full Text] [Related]

  • 44. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA.
    Cancer; 2005 Aug 15; 104(4):676-81. PubMed ID: 15981280
    [Abstract] [Full Text] [Related]

  • 45. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
    Dancer J, Takei H, Ro JY, Lowery-Nordberg M.
    Oncol Rep; 2007 Jul 15; 18(1):151-5. PubMed ID: 17549361
    [Abstract] [Full Text] [Related]

  • 46. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.
    Masuda M, Suzui M, Lim JT, Weinstein IB.
    Clin Cancer Res; 2003 Aug 15; 9(9):3486-91. PubMed ID: 12960141
    [Abstract] [Full Text] [Related]

  • 47. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M.
    In Vivo; 2007 Aug 15; 21(4):673-8. PubMed ID: 17708365
    [Abstract] [Full Text] [Related]

  • 48. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
    Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP.
    Anticancer Res; 1992 Aug 15; 12(2):419-25. PubMed ID: 1349794
    [Abstract] [Full Text] [Related]

  • 49. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ.
    Oncogene; 1994 Jul 15; 9(7):1829-38. PubMed ID: 7911565
    [Abstract] [Full Text] [Related]

  • 50. Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings.
    Molaei M, Pejhan S, Nayer BN, Moradi A, Ghiasi S, Zali MR.
    Eur J Gastroenterol Hepatol; 2009 Mar 15; 21(3):289-93. PubMed ID: 19279475
    [Abstract] [Full Text] [Related]

  • 51. Analytical approaches relating genetic evolutionary pathways to prognostic factors.
    Rohloff AC, Sakach JM, Shackney SE.
    Cytometry; 1995 Sep 01; 21(1):23-9. PubMed ID: 8529467
    [Abstract] [Full Text] [Related]

  • 52. DNA ploidy, proliferative index, and epidermal growth factor receptor: expression and prognosis in patients with gastric cancers.
    D'Agnano I, D'Angelo C, Savarese A, Carlini M, Garofalo A, Bottari L, Santoro E, Giannarelli D, Vecchione A, Zupi G.
    Lab Invest; 1995 Apr 01; 72(4):432-8. PubMed ID: 7723282
    [Abstract] [Full Text] [Related]

  • 53. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.
    Breast J; 2005 Apr 01; 11(4):278-80. PubMed ID: 15982396
    [Abstract] [Full Text] [Related]

  • 54. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
    Stark A, Lu M, Mackowiak P, Linden M.
    Breast J; 2005 Apr 01; 11(3):183-7. PubMed ID: 15871703
    [Abstract] [Full Text] [Related]

  • 55. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
    Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z.
    Hum Pathol; 2010 Nov 01; 41(11):1617-23. PubMed ID: 20688355
    [Abstract] [Full Text] [Related]

  • 56. Expression of HER-2/neu in testicular tumors.
    Mandoky L, Geczi L, Bodrogi I, Toth J, Bak M.
    Anticancer Res; 2003 Nov 01; 23(4):3447-51. PubMed ID: 12926088
    [Abstract] [Full Text] [Related]

  • 57. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.
    Stål O, Sullivan S, Sun XF, Wingren S, Nordenskjöld B.
    Cytometry; 1994 Jun 01; 16(2):160-8. PubMed ID: 7924685
    [Abstract] [Full Text] [Related]

  • 58. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
    Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, Yamashita T, Chuman H, Beppu Y, Tani Y, Hasegawa T.
    Cancer; 2005 May 01; 103(9):1881-90. PubMed ID: 15772959
    [Abstract] [Full Text] [Related]

  • 59. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C, Russell P, Boyer CM, Kerns BJ, Wiener JR, Jensen DN, Bast RC, Hacker NF.
    Cancer; 1996 May 15; 77(10):2092-8. PubMed ID: 8640675
    [Abstract] [Full Text] [Related]

  • 60. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression.
    Miller DL, el-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG.
    Cell Growth Differ; 1994 Dec 15; 5(12):1263-74. PubMed ID: 7696175
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.